Brokerages predict that Ra Pharmaceuticals Inc (NASDAQ:RARX) will report earnings per share (EPS) of ($0.49) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Ra Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.53) and the highest is ($0.44). Ra Pharmaceuticals posted earnings of ($0.51) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.9%. The company is expected to issue its next quarterly earnings results on Wednesday, November 6th.
On average, analysts expect that Ra Pharmaceuticals will report full-year earnings of ($1.97) per share for the current year, with EPS estimates ranging from ($2.08) to ($1.81). For the next year, analysts anticipate that the business will report earnings of ($2.53) per share, with EPS estimates ranging from ($2.90) to ($2.28). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.03).
Several equities research analysts have recently commented on RARX shares. Robert W. Baird began coverage on shares of Ra Pharmaceuticals in a research report on Thursday, June 20th. They issued an “outperform” rating for the company. BMO Capital Markets set a $42.00 target price on Ra Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. Svb Leerink began coverage on Ra Pharmaceuticals in a research report on Wednesday, May 22nd. They issued an “outperform” rating and a $33.00 target price for the company. Raymond James lowered Ra Pharmaceuticals from a “strong-buy” rating to a “market perform” rating in a research report on Monday, July 29th. Finally, Jefferies Financial Group raised their target price on Ra Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $38.63.
Shares of RARX traded up $0.34 during mid-day trading on Friday, hitting $25.55. 122,751 shares of the company’s stock traded hands, compared to its average volume of 455,852. The company has a quick ratio of 15.30, a current ratio of 15.30 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.20 billion, a P/E ratio of -12.40 and a beta of 1.37. The business’s 50-day moving average price is $29.92 and its 200-day moving average price is $25.86. Ra Pharmaceuticals has a 1 year low of $11.27 and a 1 year high of $36.96.
In other news, insider Ramin Farzaneh-Far sold 10,595 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $33.10, for a total transaction of $350,694.50. Following the completion of the transaction, the insider now directly owns 8,521 shares in the company, valued at $282,045.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Simon Read sold 10,000 shares of Ra Pharmaceuticals stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $22.25, for a total value of $222,500.00. Following the completion of the transaction, the insider now directly owns 8,521 shares of the company’s stock, valued at approximately $189,592.25. The disclosure for this sale can be found here. Insiders have sold 43,452 shares of company stock valued at $1,248,163 in the last ninety days. Insiders own 4.30% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in shares of Ra Pharmaceuticals by 27.9% in the second quarter. BlackRock Inc. now owns 4,059,169 shares of the company’s stock worth $122,061,000 after purchasing an additional 886,583 shares during the last quarter. Vanguard Group Inc. increased its holdings in Ra Pharmaceuticals by 19.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,564,112 shares of the company’s stock worth $47,033,000 after buying an additional 253,966 shares in the last quarter. Candriam Luxembourg S.C.A. raised its position in Ra Pharmaceuticals by 15.0% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 1,178,000 shares of the company’s stock worth $35,267,000 after buying an additional 154,000 shares during the last quarter. VHCP Management II LLC raised its position in Ra Pharmaceuticals by 7.1% in the 2nd quarter. VHCP Management II LLC now owns 677,164 shares of the company’s stock worth $20,362,000 after buying an additional 44,684 shares during the last quarter. Finally, VHCP Management III LLC lifted its stake in Ra Pharmaceuticals by 12.7% during the 2nd quarter. VHCP Management III LLC now owns 670,350 shares of the company’s stock valued at $20,157,000 after acquiring an additional 75,637 shares during the period. Institutional investors own 91.59% of the company’s stock.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Further Reading: Cost of Equity For A Business, Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.